Medidata aims to increase engagement and awareness for patients before and after clinical trials with the launch of myMedidata Registries.
myMedidata technology aims to strengthen and expand long term follow up and safety surveillance for patients before and after a clinical trial takes place.
“myMedidata Registries provides drug, vaccine, medical device sponsors with one, unified ecosystem for patient identification, study execution and end-of-study patient communications, including patient data return,” Kelly McKee vice president, Patient Recruitment and Registries for Medidata told Clinical Insider.
“Sponsors can create specific registries that are customized to meet the needs of their studies and programs—patients will be given the opportunity to join the myMedidata Registry at the time of Sponsor Registry account creation.”
The myMedidata Regsitries will intially be introduced in the US.
However, the firm is looking to expand globally in the next few months with the patient portal being available in various languages.
The technology allows contract research organizations (CROs) and sponsors to engage with participants as and when required.
According to Medidata, long term follow up and safety monitoring can be required for thousands of studies. For example, human gene therapy studies, which might need 15 to 30 years of follow up.
Furthermore, myMedidata Registries can bridge patients moving from Phase II/III to Phase IIII clinical trials.
A recent study conducted by the Center for Information and Study on Clinical Research Participation (CISCRP) revealed that only 25 percent of people reported being “very confident” in their ability to find a clinical research study.
“Issues surrounding patient awareness of and access to clinical trials have been roadblocks to participation for many years,” said McKee.
Mckee continued: “myMedidata Registries will provide patients with ongoing engagement in and out of a trial through access to one patient portal for life.”